Mersana Therapeutics is now a part of Day One Biopharmaceuticals

For more information, visit: https://www.dayonebio.com/

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer